TY - JOUR
T1 - Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer
T2 - A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup consortium
AU - Van Dorp, Wendy
AU - Mulder, Renée L.
AU - Kremer, Leontien C M
AU - Hudson, Melissa M.
AU - Van Den Heuvel-Eibrink, Marry M.
AU - Van Den Berg, Marleen H.
AU - Levine, Jennifer M.
AU - Van Dulmen-Den Broeder, Eline
AU - Di Iorgi, Natascia
AU - Albanese, Assunta
AU - Armenian, Saro H.
AU - Bhatia, Smita
AU - Constine, Louis S.
AU - Corrias, Andreas
AU - Deans, Rebecca
AU - Dirksen, Uta
AU - Gracia, Clarisa R.
AU - Hjorth, Lars
AU - Kroon, Leah
AU - Lambalk, Cornelis B.
AU - Landier, Wendy
AU - Levitt, Gill
AU - Leiper, Alison
AU - Meacham, Lillian
AU - Mussa, Alesandro
AU - Neggers, Sebastian J.
AU - Oeffinger, Kevin C.
AU - Revelli, Alberto
AU - Van Santen, Hanneke M.
AU - Skinner, Roderick
AU - Toogood, Andrew
AU - Wallace, William H.
AU - Haupt, Riccardo
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Purpose: Female survivors of childhood, adolescent, and young adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential exposure of the ovaries, have an increased risk of premature ovarian insufficiency (POI). Clinical practice guidelines can facilitate these survivors' access to optimal treatment of late effects that may improve health and quality of survival; however, surveillance recommendations vary among the existing long-term follow-up guidelines, which impedes the implementation of screening. Patients and Methods: The present guideline was developed by using an evidence-based approach and summarizes harmonized POI surveillance recommendations for female survivors of CAYA cancer who were diagnosed at age < 25 years. The recommendations were formulated by an international multidisciplinary panel and graded according to the strength of the evidence and the potential benefit gained from early detection and intervention. The harmonized POI surveillance recommendations were developed by using a transparent process and are intended to facilitate care for survivors of CAYA cancer. Results and Conclusion: The harmonized set of POI surveillance recommendations is intended to be scientifically rigorous, to positively influence health outcomes, and to facilitate the care for female survivors of CAYA cancer.
AB - Purpose: Female survivors of childhood, adolescent, and young adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential exposure of the ovaries, have an increased risk of premature ovarian insufficiency (POI). Clinical practice guidelines can facilitate these survivors' access to optimal treatment of late effects that may improve health and quality of survival; however, surveillance recommendations vary among the existing long-term follow-up guidelines, which impedes the implementation of screening. Patients and Methods: The present guideline was developed by using an evidence-based approach and summarizes harmonized POI surveillance recommendations for female survivors of CAYA cancer who were diagnosed at age < 25 years. The recommendations were formulated by an international multidisciplinary panel and graded according to the strength of the evidence and the potential benefit gained from early detection and intervention. The harmonized POI surveillance recommendations were developed by using a transparent process and are intended to facilitate care for survivors of CAYA cancer. Results and Conclusion: The harmonized set of POI surveillance recommendations is intended to be scientifically rigorous, to positively influence health outcomes, and to facilitate the care for female survivors of CAYA cancer.
UR - http://www.scopus.com/inward/record.url?scp=84990065753&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.64.3288
DO - 10.1200/JCO.2015.64.3288
M3 - Review article
C2 - 27458300
AN - SCOPUS:84990065753
SN - 0732-183X
VL - 34
SP - 3440
EP - 3450
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 28
ER -